• Mashup Score: 0
    VIDEO: Pediatric colon cancer can be prevented with screening, dysplasia detection - 7 month(s) ago

    In a Healio video exclusive, Rene D. Gomez-Esquivel, MD, discusses risk factors for pediatric colon cancer, as well as best practices for screening and lesion resection, from his presentation at the 2023 NASPGHAN annual meeting. “Colon cancer is the most common solid tumor of the GI tract in pediatrics,” Gomez-Esquivel, associate professor of medicine and pediatrics at Morsani

    Source: www.healio.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HealioGastro
      HealioGastro

      In a @GoHealio #GI 🎥 exclusive, Rene D. Gomez-Esquivel, MD, of @USFHealthMed, discussed risk factors for pediatric 👧🏻👦🏾 #coloncancer, as well as best practices for screening and lesion resection Learn more from #NASPGHAN23 below 👇🏻 https://t.co/eZv5gC9F39

  • Mashup Score: 0
    Does Colon Tumor Location Play a Role in Metastasis and Survival - The ASCO Post - 7 month(s) ago

    There have been demonstrated differences in tumor cell metabolism between right-sided and left-sided colorectal tumors, which could explain the differences observed in their clinical behavior, especially in metastatic disease. Now, new research has found that patients with right-sided colorectal tumors that spread to the liver had worse survival rates than those with left-sided tumors that had also metastasized to the liver. The findings, published by Morris et al in Cancer Letters, provide i nsight into

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Does Colon Tumor Location Matter? https://t.co/leQTLZ9Ic4 #crcsm #coloncancer

  • Mashup Score: 0
    Reducing Disparities and Achieving Health Equity in Colorectal Cancer Screening - 7 month(s) ago

    Increases in colorectal cancer screening are linked to the declining incidence of the disease over the past 3 decades. These favorable trends, however, are not observed in marginalized racial and ethnic populations with disproportionately lower rates of screening, higher disease incidence, and increased mortality, despite advances in health technology and policy. This review describes the differences in screening uptake and test selection among racial and ethnic groups, discusses known obstacles and facilitators that impact screening, and highlights existing frameworks developed to achieve health equity in colorectal cancer screening.

    Source: www.tigejournal.org
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AGA_Gastro
      AGA_Gastro

      #ColonCancer is the 3rd most common cancer in the US. While strides in screening have been made, there are persistent #disparities in screening amongst racial/ethnic groups. Equity strategies outlined https://t.co/AYoOcJsTI5 https://t.co/IzHDLubvPc

  • Mashup Score: 13
    Oncogenic KRAS drives lipo-fibrogenesis to promote angiogenesis and colon cancer progression - 7 month(s) ago

    Abstract. Oncogenic KRAS (KRAS*) contributes to many cancer hallmarks. In colorectal cancer (CRC), KRAS* suppresses anti–tumor immunity to promote tumor invasion and metastasis. Here, we uncovered that KRAS* transforms the phenotype of carcinoma-associated fibroblasts (CAFs) into lipid–laden CAFs, promoting angiogenesis and tumor progression. Mechanistically, KRAS* activates the transcription factor CP2 (TFCP2) which upregulates the expression of the pro–adipogenic factors BMP4 and WNT5B, triggering the transformation of CAFs into lipid–rich CAFs. These lipid-rich CAFs, in turn, produce vascular endothelial growth factor A (VEGFA) to spur angiogenesis. In KRAS*–driven CRC mouse models, genetic or pharmacological neutralization of TFCP2 reduced lipid-rich CAFs, lessened tumor angiogenesis, and improved overall survival. Correspondingly, in human CRC, lipid-rich CAF and TFCP2 signatures correlate with worse prognosis. This work unveils a new role for KRAS* in transforming CAFs, driving t

    Source: aacrjournals.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CD_AACR
      CD_AACR

      Oncogenic #KRAS Drives Lipo-fibrogenesis to Promote #Angiogenesis and #ColonCancer Progression, by Wen-Hao Hsu, @RonDePinho et al. https://t.co/rwDRNyf8od @MDAndersonNews https://t.co/AF2MahRbVi

  • Mashup Score: 0
    Star saxophonist, patient advocate James Casey dies of colon cancer at age 40 - 8 month(s) ago

    James Casey, acclaimed saxophonist for the Trey Anastasio Band, died Aug. 28 at age 40 after a 2-year battle with colon cancer. Earlier this year, Casey shared his diagnosis and cancer battle at the “Colorectal Cancer in Young Black Americans” webinar event, presented by the Association for Black Gastroenterologists and Hepatologists (ABGH).

    Source: www.healio.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HealioGastro
      HealioGastro

      🌟 saxophonist 🎷, patient advocate @JamesCaseySax dies of #coloncancer “His story highlights some of the challenges we [the Black community] face when we are saying what is happening with us," @vgustavemd said. @blackingastro @DrR_Williams https://t.co/UvpoM2oVQN

  • Mashup Score: 46
    FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study - 8 month(s) ago

    PURPOSE BRAFV600E mutation is associated with a poor outcome in metastatic colorectal cancer (mCRC). This clinical trial investigated the efficacy of triplet chemotherapy (fluorouracil, folinic acid, oxaliplatin, and irinotecan) combined with either cetuximab or bevacizumab in patients with previously untreated BRAFV600E-mutant mCRC. PATIENTS AND METHODS In this controlled, randomized, open-label phase II trial, 109 patients were randomly assigned, 107 of whom were included into the full analysis set (FAS). Patients were randomly assigned in a 2:1 ratio to receive either FOLFOXIRI plus cetuximab in the experimental arm (n = 72) or FOLFOXIRI plus bevacizumab in the control arm (n = 35). The primary end point was objective response rate (ORR) according to RECIST 1.1., evaluated in patients treated according to protocol (ATP population). Progression-free survival (PFS), overall survival (OS), toxicity, and feasibility were analyzed as secondary end points. RESULTS Eighteen patients discon

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      RT @ArndtVogel: FOLFOXIRI Plus Cetuximab or Bevacizumab as 1st line Treatment of mBRAFV600E #coloncancer @JCO_ASCO https://t.co/8zZ4tbI8bp…

Load More